CollPlant Biotechnologies logo

CollPlant BiotechnologiesNASDAQ: CLGN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

31 January 2018

Next earnings report:

27 November 2024

Last dividends:

N/A

Next dividends:

N/A
$47.88 M
-77%vs. 3y high
34%vs. sector
-vs. 3y high
-vs. sector
-48%vs. 3y high
61%vs. sector
-85%vs. 3y high
94%vs. sector

Price

regular market | 53 min ago
$4.18-$0.05(-1.18%)

Dividend

No data over the past 3 years
$249.00 K$1.54 M
$249.00 K-$4.21 M

Analysts recommendations

Institutional Ownership

CLGN Latest News

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
prnewswire.com12 November 2024 Sentiment: POSITIVE

- Conference call to be held on Wednesday, November 27, 2024 at 10:00 a.m. U.S. EST - REHOVOT, Israel , Nov. 12, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2024 on Wednesday, November 27, 2024, before the opening of the U.S. financial markets.

CollPlant (CLGN), Stratasys Initiate Study for Breast Implants
zacks.com21 August 2024 Sentiment: POSITIVE

CollPlant (CLGN) and Stratasys announce the initiation of a pre-clinical study to focus on the ability of implants to grow natural breast tissue and completely degrade over time.

CollPlant Biotechnologies Ltd. (CLGN) Q2 2024 Earnings Call Transcript
seekingalpha.com20 August 2024 Sentiment: POSITIVE

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q2 2024 Earnings Conference Call August 20, 2024 10:00 AM ET Company Participants Dan Ferry - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Sean Lee - H.C.

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
prnewswire.com20 August 2024 Sentiment: POSITIVE

- Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin ® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel , Aug. 20, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update.

CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
prnewswire.com06 June 2024 Sentiment: POSITIVE

Bio-printing technology now enables fabrication of 200cc implant size and above to address future commercial demand Interim pre-clinical data shows tissue growth including regeneration of maturing connective tissue as well as neovascularization, synchronized with progressive implant degradation No adverse tissue reaction was observed Large-animal studies with commercial-size implants are currently underway with results expected in Q4 2024 and Q1 2025 REHOVOT, Israel , June 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced that it has successfully printed for the first-time breast implants of 200 cc, which are commercial size. These implants were printed using CollPlant's proprietary rhCollagen bioinks.

CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
prnewswire.com29 May 2024 Sentiment: POSITIVE

Additional large-animal study with commercial-size breast implants commenced in December 2023 expected to conclude in June 2024 Cash and cash equivalents balance as of March 31, 2024, was $23.2 million Conference call and webcast to discuss its financial results and corporate updates on May 29 at 10:00 a.m. Eastern Daylight Time (details herein) REHOVOT, Israel , May 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced results for the first quarter ended 2024 and provided a corporate update.

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
prnewswire.com16 May 2024 Sentiment: POSITIVE

A conference call is scheduled for Wednesday, May 29, 2024 at 10:00 a.m. U.S. EDT. CollPlant Biotechnologies will release financial results for the first quarter of 2024 on the same day before the opening of the U.S. financial markets.

CollPlant Biotechnologies Ltd. (CLGN) Q4 2023 Earnings Call Transcript
Seeking Alpha04 April 2024 Sentiment: NEUTRAL

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2023 Earnings Conference Call April 4, 2024 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C.

CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California
PRNewsWire08 January 2024 Sentiment: POSITIVE

REHOVOT, Israel , Jan. 8, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq:  CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that Mr. Yehiel Tal, the Company's CEO, will participate in the Octane Aesthetic Tech Forum, being held on January 25-26, 2024 in Newport Beach, CA.

CollPlant Biotechnologies Ltd. (CLGN) Q3 2023 Earnings Call Transcript
Seeking Alpha29 November 2023 Sentiment: NEGATIVE

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q3 2023 Earnings Conference Call November 29, 2023 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings.

What type of business is CollPlant Biotechnologies?

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

What sector is CollPlant Biotechnologies in?

CollPlant Biotechnologies is in the Healthcare sector

What industry is CollPlant Biotechnologies in?

CollPlant Biotechnologies is in the Biotechnology industry

What country is CollPlant Biotechnologies from?

CollPlant Biotechnologies is headquartered in Israel

When did CollPlant Biotechnologies go public?

CollPlant Biotechnologies initial public offering (IPO) was on 31 January 2018

What is CollPlant Biotechnologies website?

https://www.collplant.com

Is CollPlant Biotechnologies in the S&P 500?

No, CollPlant Biotechnologies is not included in the S&P 500 index

Is CollPlant Biotechnologies in the NASDAQ 100?

No, CollPlant Biotechnologies is not included in the NASDAQ 100 index

Is CollPlant Biotechnologies in the Dow Jones?

No, CollPlant Biotechnologies is not included in the Dow Jones index

When was CollPlant Biotechnologies the previous earnings report?

No data

When does CollPlant Biotechnologies earnings report?

The next expected earnings date for CollPlant Biotechnologies is 27 November 2024